N°00 - July 2016
Biomnis News

Our new meeting point to share progress in specialised biology at the service of your daily medical practice.
Scientific information, decoding of new parameters available and their clinical interest, recommendations of knowledge societies, reports from conferences, etc. Biomnis News’ ambition is to teach healthcare professionals new issues in medical biology.

Don’t forget to sign up to receive our next Biomnis News!


Shedding light on ...

B. Quilichini

Dr B. Quilichini

How to observe a breast cancer in 10 years?
The Prosigna® prognostic test of breast cancer gene expression has been developed based on the PAM50 genetic signature, which measures the expression of 50 genes to classify tumours on the basis of molecular subtype and an algorithm that combines genomic data and clinical variables.

The Prosigna® test generates information on the risk of recurrence (RoR) for each patient tested, taking into account the size of the tumour, the intrinsic subtype, and the lymph-node status of the patient.
Take a look at the viewpoint of our expert Benoît Quilichini on the Prosigna Test ®: a prognostic gene expression test in breast cancer.

See all "Shedding light on"


Decoding :Treatment of pre-eclampsia

Every year 24,000 to 40,000 women in France are affected by pre-eclampsia (out of a total of 800,000 pregnancies).
Pre-eclampsia is a major cause of intrauterine delayed growth, responsible for one third of major severely premature births and the second cause of maternal death of obstetric origin. Identification of these at risk patients therefore represents a critical issue.
Take a look at our scientific information brochure on the screening of pre-eclampsia at different stages of pregnancy:



The panel-based molecular approach in the diagnostics for infectious deseases
Biomnis announces its collaboration with the American laboratory Diatherix in the field of diagnostics for infectious diseases.
Diatherix specialises in molecular diagnostics tests using its own TEM-PCRTM (Targeted Enriched Multiplex Polymerase Chain Reaction) technology.
This patented technology, validated by the Clinical Laboratory Standards Institute, enables the company to offer a new diagnostic approach using panels of tests for specific conditions.
Discover the advantages of the panel-based molecular approach in the diagnostics for infectious diseases.

Viadéo LinkedIn Twitter © 2016 Biomnis • Biomnis, 17 et 19 avenue Tony Garnier BP 7322 • 69357 Lyon Cedex 07 France